12/5
04:18 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/4
04:30 pm
trda
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/17
09:32 am
trda
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]
Low
Report
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]
11/6
09:01 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.
11/6
07:23 am
trda
Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/6
07:00 am
trda
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
Low
Report
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
10/28
07:00 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences
10/3
03:35 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/25
03:38 pm
trda
Entrada Therapeutics, Inc. (TRDA) Discusses On Home With HCW Call (Transcript) [Seeking Alpha]
Low
Report
Entrada Therapeutics, Inc. (TRDA) Discusses On Home With HCW Call (Transcript) [Seeking Alpha]